רווח לפני ריבית, מסים ופחת: Lixte Biotechnology Holdings, Inc. (LIXT)

Lixte Biotechnology is developing innovative LB-100 phosphatase inhibitors to enhance chemotherapy by investing in scientific potential. This chart, provided by the GURU.Markets platform, shows that EBITDA reached 0.00. Management is aggressively raising capital to achieve medical breakthroughs, while a compact staff of biochemists leverages strong ties with academic centers.

This indicator reflects net cash flow from operating activities before depreciation and interest, allowing for an assessment of the business's actual scalability without accounting adjustments. By analyzing EBITDA in cash terms, an investor can see how the automation of protein inhibitor discovery via AI modeling converts into operational efficiency, confirming the viability of the digital strategy of Lixte Biotechnology (LIXT).